Can Darling Ingredients Turn Collagen Into a Bigger Earnings Engine?

Darling Ingredients is shifting its Food segment toward collagen, which generates roughly 2.5-3.0x gelatin margins, while targeted ingredients generate 7-11x gelatin margins using existing Rousselot production infrastructure. Collagen contributed 48% of Food adjusted EBITDA in 2025, up from 35% in 2020, and is projected to reach 50% by 2030; targeted ingredients are expected to add 15% of segment EBITDA by then. DAR shares have risen 20.5% over three months and trade at a 10.07x forward P/E, versus 14.56x for its industry and 17.06x for the sector.

Analysis

The investable question is not collagen demand but whether DAR can convert mix improvement into consolidated free cash flow while its rendering and renewable-diesel-linked businesses remain more material earnings drivers. Incremental collagen sales should have unusually high drop-through because the production footprint is largely sunk; this can lift Food margins even without volume growth. A credible sequence of quarterly Food-segment margin expansion and cash conversion would justify a re-rating from a cyclical byproduct processor toward a specialty-ingredients platform over 6-18 months.

The near-term risk is that the market capitalizes an aspirational 2030 mix target before evidence of pricing durability emerges. Collagen is exposed to consumer-health and nutrition discretionary demand, while lower whey prices would weaken the substitution case; Asian demand growth also carries FX and local-competition risk. More importantly, a deterioration in renewable diesel economics, animal-fat feedstock spreads, or leverage metrics could swamp a relatively smaller Food upside and prevent multiple expansion.

Consensus likely underweights the strategic value of DAR's raw-material collection network: it creates traceability and supply assurance that branded nutrition customers increasingly require, raising switching costs versus smaller collagen suppliers. But this advantage matters only if management discloses realized price/mix, utilization and segment EBITDA bridge data; absent that disclosure, the article is not sufficient evidence of an earnings-estimate inflection.

Key Decisions for Investors

• Maintain or initiate a starter long DAR only on confirmation at the next two earnings reports that Food EBITDA margin expands year over year while consolidated net leverage declines; target a 15-25% 6-12 month upside from earnings revisions plus partial multiple normalization. Exit if Food margin fails to expand for two consecutive quarters or renewable-diesel weakness causes consolidated EBITDA guidance to fall.
• Use a 3-6 month DAR call spread rather than outright calls after a pullback: buy an at-the-money call and sell a 15-20% out-of-the-money call. This expresses a re-rating catalyst while limiting premium exposure if the collagen narrative proves too long-dated.
• Do not use CHEF, COCO, or UTZ as direct read-through trades: their earnings are driven by distribution execution, beverage demand, and snacks, respectively, rather than collagen economics. Treat their inclusion as promotional noise rather than corroboration of DAR's thesis.
• Set a diligence alert for reported collagen volume, net price/mix, Food utilization, and whey-price trends. A positive trade upgrade requires evidence that higher-margin products are displacing gelatin rather than merely growing within a weak overall Food demand environment.